North America Pneumococcal Vaccine Market Size & Outlook
Related Markets
North America pneumococcal vaccine market highlights
- The North America pneumococcal vaccine market generated a revenue of USD 6,085.9 million in 2023.
- The market is expected to grow at a CAGR of 2% from 2024 to 2030.
- In terms of segment, pneumococcal conjugate vaccine was the largest revenue generating vaccine type in 2023.
- Pneumococcal Conjugate Vaccine is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 6,085.9 million |
| Market revenue in 2030 | USD 6,996.8 million |
| Growth rate | 2% (CAGR from 2023 to 2030) |
| Largest segment | Pneumococcal conjugate vaccine |
| Fastest growing segment | Pneumococcal Conjugate Vaccine |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine |
| Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Walvax Biotechnology, Beijing Minhai Biotechnology Co. |
Other key industry trends
- In terms of revenue, North America region accounted for 75.4% of the global pneumococcal vaccine market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- MEA is the fastest growing regional market and is projected to reach USD 379.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pneumococcal Vaccine Market Scope
Pneumococcal Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Beijing Minhai Biotechnology Co. | View profile | 501-1000 | Beijing, Beijing, China, Asia | https://en.biominhai.com |
| CSL Ltd | View profile | 32000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | https://www.csl.com |
| Walvax Biotechnology | View profile | 11-50 | Kunming, Yunnan, China, Asia | http://www.walvax.com |
| Serum Institute of India Pvt. Ltd. | View profile | 1001-5000 | Pune, Maharashtra, India, Asia | http://www.seruminstitute.com/ |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
North America pneumococcal vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pneumococcal vaccine market will help companies and investors design strategic landscapes.
Pneumococcal conjugate vaccine was the largest segment with a revenue share of 93.14% in 2023. Horizon Databook has segmented the North America pneumococcal vaccine market based on pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine covering the revenue growth of each sub-segment from 2018 to 2030.
In the North America pneumococcal vaccine market, the scenario is characterized by a growing awareness of the importance of vaccination in preventing pneumococcal diseases. Government health agencies and organizations are actively promoting vaccination campaigns to combat pneumococcal infections, driving market demand.
In addition, the presence of leading pharmaceutical companies, such as Pfizer Inc. and Merck & Co., Inc., competing to develop and market advanced pneumococcal vaccines intensifies competition in the market.
The market is also influenced by factors such as disease prevalence, public health initiatives, and regulatory frameworks governing vaccine approval and distribution. As the market continues to evolve, collaboration between healthcare stakeholders and sustained investment in research and development will play pivotal roles in shaping the future landscape of the North America pneumococcal vaccine market.
Reasons to subscribe to North America pneumococcal vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America pneumococcal vaccine market databook
-
Our clientele includes a mix of pneumococcal vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America pneumococcal vaccine market, including forecasts for subscribers. This continent databook contains high-level insights into North America pneumococcal vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America pneumococcal vaccine market size, by country, 2018-2030 (US$M)
North America Pneumococcal Vaccine Market Share, 2023 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
